cpg glp-1 news adoption forces CPGs to rethink growth CPG giants reevaluate their portfolios

The medication's success underscores the value of targeting incretin pathways in treating metabolic disorders and highlights the chronic nature of conditions like obesity that benefit from ongoing management rather than short-term interventions

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide and costs to consumers will triple, from $350 a month to $1,000.

Our offerings include a selection of hydration and wellness treatments designed to support overall health and well-being.

Nausea affects up to 25% of GLP-1 users during dose titration

Contact our team today.

The product is viewed by the CPG giant as a one-of-a-kind opportunity to help consumers rebuild or maintain muscle they lose when taking weight loss drugs such as Ozempic.